Japanese Firm Santen Pharmaceutical Completes Suzhou Plant
This article was originally published in PharmAsia News
Santen Pharmaceutical, Japan's top ophthalmic medicine maker, recently held an opening ceremony for its Suzhou plant. The firm invested about ¥2.3 billion (RMB 147 million) in the facility - the first production base of Santen in China - which is expected to produce 20 million vials of eye drops annually or about 10 percent of its global output. Since 1988, Santen has set up representative offices in Beijing, Shanghai and Guangzhou. Its key products Tarivid (ofloxacin) and Cravit (levofloxacin) together hold 35 percent of the local hospitals' anti-bacteria eye drop market share with total sales exceeding RMB 110 million. Santen aims to increase its revenue in China three fold by 2015. (Click here for more - Chinese Language)
You may also be interested in...
Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.
With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.